HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2 OF ID/IQ CONTRACT NO. HHSN271201800001I

Albany Molecular Research, Inc., Albany NY

Investigators

Abstract

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. Hit to Lead Chemistry (Task Order)) is hereby awarded to Curia Global, Inc. (Contractor) under ID/IQ Contract HHSN271201800001I (Parent Contract). to develop structure activity relationship (SAR) analysis and design, synthesis, in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET), computational chemistry/Computer Aided Drug Discovery (CADD), and compound logistics of storage and shipping to support the Contributor in developing a novel therapeutic effective in treating pain. This will be achieved by advancing the SAR/SPR of their small molecule prodrugs of starting small molecules utilizing their assays and in vitro ADMET to identify novel, prodrugs.